IFF stock forecast 2027–2029
MyStockButler's October 2026 analysis: The weighted forecast points to $57.31 by October 2029, with 35% bear, 50% base and 15% bull probabilities. It hinges on growth, the Food Ingredients sale, cash conversion and cost removal.
Where could IFF's shares be by 2029?
The weighted forecast points to $57.31 by October 2029, a 32% loss with dividends, and depends on growth, the Food Ingredients sale, cash conversion and cost removal. Management guides to continuing sales of $7.4–$7.6 billion and adjusted operating EBITDA of $1.53–$1.60 billion for 2026. It expects the sale to provide about $3.8 billion in net cash by Q2 2027, with debt reduction and the remaining $2.0 billion of repurchases dependent on closing.
The forecast puts the weighted price at $49.78 in October 2027, a 44% loss with dividends, then $57.31 in October 2029, a 32% loss with dividends. The probabilities are 35% bear, 50% base and 15% bull.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 35 % | 28.77 (-67 %) | 27.52 (-68 %) | 26.68 (-68 %) |
| Base | 50 % | 56.55 (-36 %) | 59.63 (-31 %) | 62.27 (-26 %) |
| Bull | 15 % | 76.25 (-14 %) | 93.56 (+6 %) | 112.26 (+29 %) |
| Weighted | 100 % | 49.78 (-44 %) | 53.48 (-38 %) | 57.31 (-32 %) |
What this means. The weighted row is the probability-based average of the bear, base, and bull cases, not a guaranteed price.
What has to go right for IFF's stock forecast?
The base path uses the company’s $7.4 billion to $7.6 billion 2026 sales guidance as its starting point, but assumes net income improves more slowly than adjusted EBITDA because depreciation, interest and tax remain. Recent comparable growth was 4% in Taste and 5% in Health & Biosciences, while Scent reached 8%. The bear case allows for weaker volume, delayed cost removal and limited debt benefit. The bull case requires sustained launches, pricing, sourcing gains and faster stranded-cost removal. The forecast excludes the $360 million tax benefit and $488 million debt-retirement gain from 2025 because they were exceptional.
The bear case assumes volume weakens, price recovery slows and Food Ingredients closing is delayed. Stranded costs remain, cash conversion disappoints and buybacks arrive later. The price falls to $28.77 in October 2027 and $26.68 by October 2029. Its probability is 35% because IFF has experienced volume setbacks, uneven guidance delivery and free cash flow below dividends.
How much cash does IFF really make?
In 2025, IFF’s free cash flow was reduced further by capital spending. An owner may also subtract stock compensation because it gives employees a claim on future shareholder value, even though it does not consume cash immediately. That creates a stricter analytical measure than IFF’s own count.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 850 | 1,070 | 1,455 | 397 | 1,437 |
| − Capital spending | 594 | 463 | 503 | 504 | 393 |
| = Free cash flow | 256 | 607 | 952 | -107 | 1,044 |
| − Stock pay | 88 | 77 | 65 | 49 | 54 |
| = Real free cash flow | 168 | 530 | 887 | -156 | 990 |
| Free cash flow — the company's own count | 256 | 607 | 936 | -107 | 1,044 |
What this means. The company's own free cash flow is 16 million dollars lower in 2023 because it used a later correction to cash from operations, not because it subtracts another cost.
What does an investor pay for IFF today?
| Today (Oct 21, 2026) | |
|---|---|
| Share price | 91.03 |
| Market value (calculated) | 23,226.30 |
| Enterprise value (calculated) | 28,392.30 |
| P/E, last 12 months (calculated) | 74.0x |
| P/E, next 12 months (calculated) | 27.0x |
| Real free cash flow yield (calculated) | 0.7% |
What this means. The price-to-earnings ratio falls from 74.0 to 27.0 because the first uses past profit while the second uses analysts’ expected future profit, which may not happen.